JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Medicine

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published: September 17th, 2021

DOI:

10.3791/62558

1Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine

Myocardial lactate production (coronary arterial-venous difference in serum lactate level) during coronary spasm provocation testing is considered as a highly sensitive marker that reflects acetylcholine-induced myocardial ischemia due to microvascular spasm. This article presents the procedures to assess myocardial lactate production for the diagnosis of coronary microvascular spasm.

In about a quarter of patients with angina and non-obstructive coronary arteries, no epicardial spasm is noted on coronary arteriography during an angina attack. Since the pressure-rate product is almost identical at rest and the onset of attack in those patients, the decrease in coronary blood flow rather than increased myocardial oxygen consumption is likely to explain myocardial ischemia, indicating a substantial involvement with coronary microvascular spasm (MVS). Myocardial lactate production, which could be defined as a negative myocardial lactate extraction ratio (ratio of the coronary arterial-venous difference in lactate concentration to arterial concentration), is considered indicative of objective evidence to support the emerging myocardial ischemia. Thus, monitoring of the myocardial lactate production and the emergence of chest pain and ischemic electrocardiographic changes during acetylcholine (ACh) provocation testing is of significant value for detecting the entity of MVS. Practically, 1 min after incremental doses of ACh (20, 50, and 100 μg) are administered into the left coronary artery (LCA), paired samples of 1 mL of blood are collected from the LCA ostium and coronary sinus for measurement of lactate concentration by a calibrated automatic lactate analyzer. Then, the development of MVS could be confirmed by negative myocardial lactate extraction ratio despite the absence of angiographically demonstrable epicardial coronary spasm or before its occurrence throughout ACh provocation testing. In conclusion, assessment of myocardial lactate production is essential and valuable for the diagnosis of MVS.

Recent studies demonstrated that ischemia with non-obstructive coronary arteries (INOCA) is caused mainly by functional coronary vasomotion disorders, including epicardial and microvascular spasms1. The diagnosis of coronary vasoconstrictor dysfunction at the epicardial and/or microvascular levels often requires intracoronary provocation testing with a pharmacological vasoactive agent such as acetylcholine (ACh) during coronary angiography2. Many patients with INOCA have no epicardial spasm on coronary arteriography despite the development of angina attack and ischemic electrocardiographic (ECG) changes in response to in....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

The measurement of myocardial lactate production during ACh provocation testing to evaluate coronary vasoreactivity was conducted following the ethical principles in the Declaration of Helsinki, and the protocol was approved by the Ethics Committees of Tohoku University (No.2016-1-643). All the patients provided written informed consent before the procedure. In this article, ACh provocation testing was performed following the guidelines of the Japanese Circulation Society9.

Log in or to access full content. Learn more about your institution’s access to JoVE content here

A 56-year-old woman with no coronary risk factors suffered from transient chest discomfort at rest. She underwent ACh provocation testing and measurement of myocardial lactate production for diagnosis of MVS. As shown in Figure 2, chest pain, ischemic ECG changes, and negative LER were noted immediately following 100 µg of ACh administration into the LCA. Still, no relevant epicardial coronary spasm was observed on angiography. Thus, she was diagnosed as having MVS. Intriguingly, she ha.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Detection of enhanced coronary vasoconstriction is possible by an additional pharmacological provocation testing with ACh or ergometrine during coronary angiography. Even now, there is no technique to directly visualize the coronary microvasculature for evaluation of its function in vivo, the occurrence of coronary spasm at microvascular level could be solely deduced by the reproduction of usual symptoms together with ischemic ECG changes despite the absence of epicardial coronary spasm during ACh provocation te.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

We thank all the staff of the catheterization laboratory of the Tohoku University Hospital.

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

Name Company Catalog Number Comments
ABL8000 FLEX blood gas analyzer RADIOMETER, Copenhagen, Denmark k041874 The automatic lactate analyzer
OUTLOOK Terumo Corp, Tokyo, Japan RQ-5JL4000 The Judkins-left catheter for coronary angiography
Ovisot for injection Daiichi sankyo company, limited, Tokyo, Japan 871232 Injectable product of acetylcholine chloride for acetylcholine provocation testing
Supersheath MEDIKIT CO., LTD., Tokyou, Japan CS50P11TSM The sheath for insertion of a catheter
Technowood SoftNAV Catheter Technowood Corp, Tokyo, Japan H710-FL445SH The Amplatz-left catheter for blood sampling from coronary sinus

  1. Kunadian, V., et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal. 41 (37), 3504-3520 (2020).
  2. Ong, P., et al. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovascular Research. 116 (4), 841-855 (2020).
  3. Mohri, M., et al. Angina pectoris caused by coronary microvascular spasm. Lancet. 351 (9110), 1165-1169 (1998).
  4. Sun, H., et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. Journal of the American College of Cardiology. 39 (5), 847-851 (2002).
  5. Ong, P., et al. International standardization of diagnostic criteria for microvascular angina. International Journal of Cardiology. 250, 16-20 (2018).
  6. Matsuyama, K., et al. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. American Journal of Cardiology. 68 (10), 991-995 (1991).
  7. Goldberg, S., et al. Coronary hemodynamic and myocardial metabolic alterations accompanying coronary spasm. American Journal of Cardiology. 43 (3), 481-487 (1979).
  8. Odaka, Y., et al. Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries. European Heart Journal. 38 (7), 489-496 (2017).
  9. J. C. S. Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circulation Journal. 78 (11), 2779-2801 (2014).
  10. Kaikita, K., et al. Determinants of myocardial lactate production during acetylcholine provocation test in patients with coronary spasm. Journal of American Heart Association. 4 (12), (2015).
  11. Sueda, S., Kohno, H., Ochi, T., Uraoka, T. Overview of the acetylcholine spasm provocation test. Clinical Cardiology. 38 (7), 430-438 (2015).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved